Table 2. Impact of clinicopathological factors and protein expression/activation on patient survival.
|
Total patient cohort (274 patients)
|
Univariate analysis
|
Multivariate analysis
|
|||||
|---|---|---|---|---|---|---|---|
| Variables | Numbers | P-value | HR | IQR | P-value | HR | IQR |
| Age (<50/>50 years) | 68/206 | 0.365 | 1.3 | 0.7–2.4 | |||
| Tumour type (ductal/lobular/tubular/others) | 260/9/2/3 | 0.774 | 0.7 | 0.3–1.6 | |||
| Grade (G1/G2/G3) | 20/122/132 | 0.030 | 1.8 | 1.2–2.8 | 0.659 | ||
| Size (<20/20–50/>50 mm) | 111/148/15 | <0.001 | 3.8 | 2.4–6.0 | <0.001 | 12.2 | 5.4–27.8 |
| Lymph node (positive/negative) | 132/142 | <0.001 | 2.5 | 1.5–4.1 | 0.018 | 1.9 | 1.1–3.2 |
| ER status (positive/negative) | 180/94 | <0.001 | 2.3 | 1.4–3.8 | <0.001 | 2.5 | 1.5–4.1 |
| PgR status (positive/negative) | 132/140 | 0.009 | 1.9 | 1.2–3.2 | 0.579 | ||
| HER2 status (positive/negative) | 38/236 | 0.001 | 2.5 | 1.4–4.3 | 0.281 | ||
| c-Src nuc expression (positive/negative) | 129/145 | 0.399 | 1.2 | 0.7–2.0 | |||
| c-Src cyto expression (positive/negative) | 118/156 | 0.013 | 1.8 | 1.1–3.0 | 0.131 | ||
| c-Src memb expression (positive/negative) | 113/161 | 0.787 | 1.9 | 1.2–3.2 | |||
| Lyn nuc expression (positive/negative) | 66/116 | 0.742 | 0.9 | 0.5–1.7 | |||
| Lyn cyto expression (positive/negative) | 61/121 | 0.997 | 1.0 | 0.5–1.9 | |||
| Lyn memb expression (positive/negative) | 9/173 | 0.825 | 1.1 | 0.3–3.7 | |||
| Lck nuc expression (positive/negative) | 116/158 | 0.148 | 0.7 | 0.4–1.1 | |||
| Lck cyto expression (positive/negative) | 117/157 | 0.964 | 1.0 | 0.9–1.0 | |||
| Lck memb expression (positive/negative) | 14/260 | 0.039 | 0.1 | 0.01–4.0 | 0.972 | ||
| Ki67 (<5/5–20/>20) | 261/91/30 | 0.254 | 1.0 | 0.5–1.9 | |||
Abbreviations: c-Src=total Src kinase; c-Src cyto=c-Src cytoplasmic expression; c-Src memb=c-Src membrane expression; c-Src nuc=c-Src nuclear expression; ductal=ductal carcinoma; ER=oestrogen receptor; Grade=Bloom and Richardson grade; HER2=human epidermal growth factor receptor 2; HR=hazards ratio; IQR=interquartile range; Ki67=Ki67 proliferation score, low <5, moderate 5–20, high >20; Lck cyto=Lck cytoplasmic expression; Lck memb=Lck membrane expression; Lck nuc=Lyn nuclear expression; Lyn cyto=Lyn cytoplasmic expression; Lyn memb=Lyn membrane expression; Lyn nuc=Lyn nuclear expression; others=mucinous, mucoid and micropapillary carcinoma; PgR=progesterone receptor; tubular=tubular carcinoma.
The table shows an overview of the full patient cohort's characteristics. Each clinical and pathological parameter was correlated to disease-specific survival (P-values). Bold typeface is used to highlight significant P-values.